INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES

• US 20150306117A1
• Filed: 03/13/2015
• Published: 10/29/2015
• Est. Priority Date: 03/17/2010
• Status: Abandoned Application

• Current Assignee: nv nutricia
• Original Assignee: nv nutricia
• Inventors: VAN DER BEEK, Eline Marleen, ABRAHAMSE-BERKEVELD, Marieke, SCHIPPER, Annemiek Lidewij, SPEELMANS, Gelske
• Application Number:
  US14/658,054
• Publication Number:
  US 20150306117A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A23D 7/011 Compositions other than spreads
• CPC Class Codes: A23D 9/013 Other fatty acid esters, e.g. phosphatides
• CPC Class Codes: A23D 9/05 Forming free-flowing pieces
• CPC Class Codes: A23L 33/115 Fatty acids or derivatives thereof; Fats or oils
• CPC Class Codes: A23L 33/12 Fatty acids or derivatives thereof
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23P 10/35 with oils, lipids, monoglycerides or diglycerides
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/222 Emulsifier
• CPC Class Codes: A23V 2200/224 Encapsulating agent
• CPC Class Codes: A23V 2200/254 Particle size distribution
• CPC Class Codes: A23V 2200/322 having an effect on the health of the nervous system or on mental function
• CPC Class Codes: A23V 2250/1868 Docosahexaenoic acid
• CPC Class Codes: A23V 2250/187 Eicosapentaenoic acid
• CPC Class Codes: A23V 2250/1882 Polyunsaturated fatty acids
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/201 having one or two double bonds, e.g. oleic, linoleic acids
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 31/683 Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• CPC Class Codes: A61K 31/685 : one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 9/0087 : Galenical forms not covered by A61K9/02 - A61K9/7023
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 : Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 : Anxiolytics
• CPC Class Codes: A61P 25/24 : Antidepressants
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/32 : Alcohol-abuse

Abstract

The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes.

Claims

1. A method for altering brain membrane fatty acid composition selected from the group consisting of i) increasing brain membrane fluidity, ii) increasing brain membrane PUFA, iii) increasing brain membrane LC-PUFA, iv) decreasing brain membrane ratio of n6/n3 LC-PUFA, v) decreasing brain membrane ratio of n6/n3 PUFA, vi) increasing brain membrane n3 PUFA, vii) increasing brain membrane n3 LC-PUFA and viii) increasing brain membrane DHA, in a human subject, the method comprising administering to the human subject a nutritional composition comprising:

10 to 50 wt. % vegetable lipids based on dry weight of the composition, and lipid globules with a core comprising said vegetable lipids wherein said lipid globules have;

(i) a volume-weighted mode diameter above 1.0 μ

m, and/or

(ii) a diameter of 2 to 12 μ

m in an amount of at least 45 volume % based on total lipid.

2. The method according to claim 1, wherein the lipid globules have:

(i) a volume-weighted mode diameter between 1.0 and 10 μ

m, and/or

(ii) a diameter of 2 to 12 μ

m in an amount of at least 55 volume % based on total lipid.

3. The method according to claim 1, wherein the nutritional composition comprises:

(a) 0.5 to 20 wt. % phospholipids based on total lipid and/or

(b) 0.6 to 25 wt. % of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol, and comprising lipid globules with a core comprising said vegetable lipids and a coating comprising said phospholipids or polar lipids.

4. The method according to claim 1, wherein the composition comprises n3 LC-PUFA in an amount of at least 0.2 wt. % of the total fatty acid content and that does not exceed 15 wt. % of the total fatty acid content.

5. The method according to claim 1, wherein the composition comprises DHA in an amount of 0.1 to 0.6 wt. % based on total fatty acid content.

6. The method according to claim 1, wherein the composition comprises n6 LC-PUFA in an amount of at least 0.02 wt. % of the total fatty acid content and that does not exceed 5 wt. % of the total fatty acid content.

7. The method according to claim 1, wherein the composition comprises ARA in an amount of 0.1 to 0.6 wt. % based on total fatty acid content.

8. The method according to claim 1, wherein the nutritional composition comprises linoleic acid (LA) and alpha-linolenic acid (ALA) in a weight ratio LA:

ALA between 4 and 7.

9. The method according to claim 1, wherein the phospholipids are derived from milk.

10. The method according to claim 1, for altering brain membrane fatty acid composition selected from the group consisting of increasing brain membrane fluidity, increasing brain membrane PUFA, increasing brain membrane LC-PUFA, decreasing ratio of brain membrane n6/n3 LC-PUFA, decreasing ratio of brain membrane n6/n3 PUFA, increasing brain membrane n3 PUFA, increasing brain membrane n3 LC-PUFA, increasing brain membrane DHA, amelioration of cognitive performance, behavioral performance, visual acuity and fine motor skills when said human subject has reached an age above 36 months.

11. A method for amelioration of cognitive performance in a human subject above 36 months of age, the method comprising administering to said human subject at an age between 0 and 36 months a nutritional composition comprising:

10 to 50 wt. % vegetable lipids based on dry weight of the composition, and lipid globules with a core comprising said vegetable lipids, wherein said lipid globules have;

(i) a volume-weighted mode diameter above 1.0 μ

m, and/or

(ii) a diameter of 2 to 12 μ

m in an amount of at least 45 volume % based on total lipid.

12. The method according to claim 11, wherein the nutritional composition comprises:

(a) 0.5 to 20 wt. % phospholipids based on total lipid and/or

(b) 0.6 to 25 wt. % of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol, and comprising lipid globules with a core comprising said vegetable lipids and a coating comprising said phospholipids or polar lipids.

13. The method according to claim 11, wherein the composition comprises n3 LC-PUFA in an amount of at least 0.2 wt. % of the total fatty acid content and that does not exceed 15 wt. % of the total fatty acid content.

14. The method according to claim 11, wherein the composition comprises DHA in an amount of 0.1 to 0.6 wt. % based on total fatty acid content.

15. The method according to claim 11, wherein the composition comprises n6 LC-PUFA in an amount of at least 0.02 wt. % of the total fatty acid content and that does not exceed 5 wt. % of the total fatty acid content.

16. The method according to claim 11, wherein the composition comprises ARA in an amount of 0.1 to 0.6 wt. % based on total fatty acid content.

17. A method for the prevention and/or treatment of a disorder associated with decreased brain membrane fluidity and/or associated with decreased brain membrane PUFA content and/or LC-PUFA content and/or increased ratio of n6/n3 LC-PUFA, and/or increased ratio of n6/n3 PUFA, the method comprising administering to a human subject in need thereof a nutritional composition comprising:

10 to 50 wt. % vegetable lipids based on dry weight of the composition, and lipid globules with a core comprising said vegetable lipids wherein said lipid globules have;

(i) a volume-weighted mode diameter above 1.0 μ

m, and/or

(ii) a diameter of 2 to 12 μ

m in an amount of at least 45 volume % based on total lipid.

18. The method according to claim 17, wherein the disorder is a psychiatric, psychological and/or neurobiological disorder.

19. The method according to claim 17 for treatment and/or prevention of a disorder selected from the group consisting of attention deficiency, ADHD, autism, dyslexia, depression, bipolar depression, anxiety, schizophrenia, obsessive compulsive disorder, bulimia, abuse of alcohol or drugs, borderline personality disorder, panic disorder, social phobia, learning difficulties, mild cognitive impairment, learning memory impairment, language development impairment, dementia, Alzheimer'"'"'s disease and Parkinson'"'"'s disease in the human subject.

20. A nutritional composition comprising:

10 to 50 wt. % vegetable lipids based on dry weight of the composition, and lipid globules with a core comprising said vegetable lipids wherein said lipid globules have;

(i) a volume-weighted mode diameter above 1.0 μ

m, and/or

(ii) a diameter of 2 to 12 μ

m in an amount of at least 45 volume % based on total lipid.